Skip to main content

Advertisement

SpringerLink
Log in

Rationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab)

  • Treatment of Autoimmunity
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

CD6 is a cell surface receptor expressed on the majority of T cells and a subset of B cells. When expressed, CD6 contributes to lymphocyte activation through its extracellular domain 1, while adhesion and cellular migration are related to the extracellular scavenger receptor cysteine-rich domain (SRCR-D)-3 of CD6. Itolizumab, clone T1h, is a newly developed humanized IgG1 monoclonal antibody that targets CD6 SRCR-D1 and blocks immune activation. Itolizumab has been proposed to be effective in autoimmune diseases such as rheumatoid arthritis, Sjögren’s syndrome and multiple sclerosis. In Sjögren’s syndrome, the utilization of itolizumab as therapeutic option is reinforced by our recent observation that ALCAM, the CD6 ligand, is overexpressed and that CD6-positive T and B cells are detected within salivary glands from Sjögren’s syndrome patients. In this study, itolizumab-positive target cells were characterized within both peripheral blood and salivary glands in order to provide rational for anti-CD6 treatment in Sjögren’s syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Tobon GJ, Pers JO, Devauchelle-Pensec V, Youinou P. Neurological Disorders in Primary Sjogren’s Syndrome. Autoimmune Dis. 2012.

  2. Roguedas AM, Pers JO, Lemasson G, Devauchelle V, Tobon GJ, Saraux A, Misery L, Youinou P. Memory B-cell aggregates in skin biopsy are diagnostic for primary Sjogren’s syndrome. J Autoimmun. 2010;35:241–7.

    Article  PubMed  CAS  Google Scholar 

  3. Youinou P, Devauchelle-Pensec V, Pers JO. Significance of B cells and B cell clonality in Sjogren’s syndrome. Arthritis Rheum. 2010;62:2605–10.

    Article  PubMed  CAS  Google Scholar 

  4. Agmon-Levin N, Kivity S, Tzioufas AG, Lopez Hoyos M, Rozman B, Efes I, Shapira Y, Shamis A, Amital H, Youinou P, Shoenfeld Y. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjogren’s syndrome. J Autoimmun. 2012;39:234–9.

    Article  PubMed  CAS  Google Scholar 

  5. Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun. 2010;34:J207–19.

    Article  PubMed  CAS  Google Scholar 

  6. Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM. HLA and Sjogren’s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. 2012;11:281–7.

    Article  PubMed  CAS  Google Scholar 

  7. Le Dantec C, Varin MM, Brooks WH, Pers JO, Youinou P, Renaudineau Y. Epigenetics and Sjogren’s syndrome. Curr Pharm Biotechnol. 2012;13:2046–53.

    Article  PubMed  Google Scholar 

  8. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, Berthou C, Saraux A, Youinou P. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren’s syndrome. Arthritis Rheum. 2007;56:1464–77.

    Article  PubMed  Google Scholar 

  9. Varin MM, Guerrier T, Devauchelle-Pensec V, Jamin C, Youinou P, Pers JO. In Sjogren’s syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun Rev. 2012;11:252–8.

    Article  PubMed  CAS  Google Scholar 

  10. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjogren’s syndrome. J Autoimmun. 2010;34:400–7.

    Article  PubMed  CAS  Google Scholar 

  11. Daridon C, Pers JO, Devauchelle V, Martins-Carvalho C, Hutin P, Pennec YL, Saraux A, Youinou P. Identification of transitional type II B cells in the salivary glands of patients with Sjogren’s syndrome. Arthritis Rheum. 2006;54:2280–8.

    Article  PubMed  CAS  Google Scholar 

  12. Cornec D, Devauchelle-Pensec V, Tobon GJ, Pers JO, Jousse-Joulin S, Saraux A. B cells in Sjogren’s syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun. 2012;39:161–7.

    Article  PubMed  CAS  Google Scholar 

  13. Alonso R, Buors C, Le Dantec C, Hillion S, Pers JO, Saraux A, Montero E, Marianowski R, Loisel S, Devauchelle V, Youinou P, Renaudineau Y. Aberrant expression of CD6 on B-cell subsets from patients with Sjogren’s syndrome. J Autoimmun. 2010;35:336–41.

    Article  PubMed  CAS  Google Scholar 

  14. Levesque MC, Heinly CS, Whichard LP, Patel DD. Cytokine-regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte-lineage cells and in rheumatoid arthritis synovium. Arthritis Rheum. 1998;41:2221–9.

    Article  PubMed  CAS  Google Scholar 

  15. Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H, Haqqani AS, Kreymborg K, Krug S, Moumdjian R, Bouthillier A, Becher B, Arbour N, David S, Stanimirovic D, Prat A. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol. 2008;9:137–45.

    Article  PubMed  CAS  Google Scholar 

  16. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C, Briskin R, Romano S, Baranzini SE, McCauley JL, Pericak-Vance MA, Haines JL, Gibson RA, Naeglin Y, Uitdehaag B, Matthews PM, Kappos L, Polman C, McArdle WL, Strachan DP, Evans D, Cross AH, Daly MJ, Compston A, Sawcer SJ, Weiner HL, Hauser SL, Hafler DA, Oksenberg JR. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41:776–82.

    Article  PubMed  Google Scholar 

  17. Kofler DM, Severson CA, Mousissian N, De Jager PL, Hafler DA. The CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4 + T cell proliferation. J Immunol. 2011;187:3286–91.

    Article  PubMed  CAS  Google Scholar 

  18. Krintel SB, Essioux L, Wool A, Johansen JS, Schreiber E, Zekharya T, Akiva P, Ostergaard M, Hetland ML. CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. PLoS ONE. 2012;7:e38539.

    Article  PubMed  CAS  Google Scholar 

  19. Oliveira MI, Goncalves CM, Pinto M, Fabre S, Santos AM, Lee SF, Castro MA, Nunes RJ, Barbosa RR, Parnes JR, Yu C, Davis SJ, Moreira A, Bismuth G, Carmo AM. CD6 attenuates early and late signaling events, setting thresholds for T-cell activation. Eur J Immunol. 2012;42:195–205.

    Article  PubMed  CAS  Google Scholar 

  20. Roque-Navarro L, Mateo C, Lombardero J, Mustelier G, Fernandez A, Sosa K, Morrison SL, Perez R. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics. 2003;22:245–57.

    Article  PubMed  CAS  Google Scholar 

  21. Alonso R, Huerta V, de Leon J, Piedra P, Puchades Y, Guirola O, Chinea G, Montero E. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody. Hybridoma (Larchmt). 2008;27:291–301.

    Article  CAS  Google Scholar 

  22. Alonso-Ramirez R, Loisel S, Buors C, Pers JO, Montero E, Youinou P, Renaudineau Y. Rationale for targeting CD6 as a treatment for autoimmune diseases. Arthritis. 2010;2010:130646.

    Article  PubMed  Google Scholar 

  23. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–8.

    Article  PubMed  CAS  Google Scholar 

  24. Daniels TE. Labial salivary gland biopsy in Sjogren’s syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum. 1984;27:147–56.

    Article  PubMed  CAS  Google Scholar 

  25. Guellec D, Cornec D, Jousse-Joulin S, Marhadour T, Marcorelles P, Pers JO, Saraux A, Devauchelle-Pensec V. Diagnostic value of labial minor salivary gland biopsy for Sjogren’s syndrome: a systematic review. Autoimmun Rev. 2013;12:416–20.

    Article  PubMed  Google Scholar 

  26. Braun M, Muller B, ter Meer D, Raffegerst S, Simm B, Wilde S, Spranger S, Ellwart J, Mosetter B, Umansky L, Lerchl T, Schendel DJ, Falk CS. The CD6 scavenger receptor is differentially expressed on a CD56 natural killer cell subpopulation and contributes to natural killer-derived cytokine and chemokine secretion. J Innate Immun. 2011;3:420–34.

    Article  PubMed  CAS  Google Scholar 

  27. Castro MA, Oliveira MI, Nunes RJ, Fabre S, Barbosa R, Peixoto A, Brown MH, Parnes JR, Bismuth G, Moreira A, Rocha B, Carmo AM. Extracellular isoforms of CD6 generated by alternative splicing regulate targeting of CD6 to the immunological synapse. J Immunol. 2007;178:4351–61.

    PubMed  CAS  Google Scholar 

  28. Patel NC, Chinen J, Rosenblatt HM, Hanson IC, Brown BS, Paul ME, Abramson SL, Ritz J, Shearer WT. Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. J Allergy Clin Immunol. 2008;122:1185–93.

    Article  PubMed  CAS  Google Scholar 

  29. Montero E, Falcon L, Morera Y, Delgado J, Amador JF, Perez R. CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease. Autoimmunity. 1999;29:155–6.

    Article  PubMed  CAS  Google Scholar 

  30. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011;3:76–99.

    Article  PubMed  Google Scholar 

  31. Beck A, Wurch T, Reichert JM. 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland. MAbs. 2011;3:111–32.

    Article  PubMed  Google Scholar 

  32. Rodriguez PC, Torres-Moya R, Reyes G, Molinero C, Prada D, Lopez AM, Hernandez IM, Hernandez MV, Martinez JP, Hernandez X, Casaco A, Ramos M, Avila Y, Barrese Y, Montero E, Hernandez P. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Results Immunol. 2012;2:204–11.

    Article  Google Scholar 

  33. Le Pottier L, Devauchelle V, Fautrel A, Daridon C, Saraux A, Youinou P, Pers JO. Ectopic germinal centers are rare in Sjogren’s syndrome salivary glands and do not exclude autoreactive B cells. J Immunol. 2009;182:3540–7.

    Article  PubMed  Google Scholar 

  34. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Roue IQ, Cochener B, Youinou P, Saraux A. Improvement of Sjogren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57:310–7.

    Article  PubMed  CAS  Google Scholar 

  35. Singh N, Cohen PL. The T cell in Sjogren’s syndrome: force majeure, not spectateur. J Autoimmun. 2012;39:229–33.

    Article  PubMed  CAS  Google Scholar 

  36. Mageed RA, Garaud S, Taher TE, Parikh K, Pers JO, Jamin C, Renaudineau Y, Youinou P. CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte. Autoimmun Rev. 2012;11:795–8.

    Article  PubMed  CAS  Google Scholar 

  37. Singer NG, Fox DA, Haqqi TM, Beretta L, Endres JS, Prohaska S, Parnes JR, Bromberg J, Sramkoski RM. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int Immunol. 2002;14:585–97.

    Article  PubMed  CAS  Google Scholar 

  38. Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J Exp Med. 1998;188:2301–11.

    Article  PubMed  CAS  Google Scholar 

  39. Hippen KL, Tze LE, Behrens TW. CD5 maintains tolerance in anergic B cells. J Exp Med. 2000;191:883–90.

    Article  PubMed  CAS  Google Scholar 

  40. Renaudineau Y, Nedellec S, Berthou C, Lydyard PM, Youinou P, Pers JO. Role of B-cell antigen receptor-associated molecules and lipid rafts in CD5-induced apoptosis of B CLL cells. Leukemia. 2005;19:223–9.

    Article  PubMed  CAS  Google Scholar 

  41. Osorio LM, De Santiago A, Aguilar-Santelises M, Mellstedt H, Jondal M. CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Blood. 1997;89:2833–41.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the “Association Française du Gougerot-Sjögren et des syndromes secs” and from the “Ligue contre le cancer” (Comités 22, 29 and 56). The authors are grateful to Simone Forest and Geneviève Michel for secretarial assistance.

Author information

Authors and Affiliations

  1. EA 2216 “Immunology and Pathology”, Brest University Medical School, SFR ScinBios, University of Brittany, Brest, France

    Christelle Le Dantec, Ruby Alonso, Tinhinane Fali, Valérie Devauchelle, Alain Saraux, Jacques-Olivier Pers & Yves Renaudineau

  2. Experimental Immunotherapy Department, Center for Molecular Immunology, La Habana, Cuba

    Ruby Alonso & Enrique Montero

  3. Unit of Rheumatology, CHRU Cavale Blanche, Brest, France

    Valérie Devauchelle & Alain Saraux

  4. Laboratory of Immunology and Immunotherapy, CHRU Morvan, Brest, France

    Yves Renaudineau

  5. Laboratory of Immunology, Brest University Medical School Hospital, 2 avenue Foch, BP 824, F-29609, Brest, France

    Yves Renaudineau

Authors
  1. Christelle Le Dantec
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruby Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tinhinane Fali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Enrique Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valérie Devauchelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alain Saraux
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jacques-Olivier Pers
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yves Renaudineau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yves Renaudineau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Le Dantec, C., Alonso, R., Fali, T. et al. Rationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab). Immunol Res 56, 341–347 (2013). https://doi.org/10.1007/s12026-013-8423-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-013-8423-x

Keywords

Search

Navigation